Home/Filings/4/0001053369-13-000034
4//SEC Filing

POTTI RAM 4

Accession 0001053369-13-000034

CIK 0001053369other

Filed

Apr 29, 8:00 PM ET

Accepted

Apr 30, 3:07 PM ET

Size

18.2 KB

Accession

0001053369-13-000034

Insider Transaction Report

Form 4
Period: 2013-04-25
POTTI RAM
Director10% Owner
Transactions
  • Conversion

    Common Stock

    2013-04-26+8,230,45324,668,546 total(indirect: see footnote)
  • Other

    Common Stock

    2013-04-29$0.04/sh13,367,481$493,26015,626,892 total(indirect: see footnote)
  • Disposition to Issuer

    Common Stock

    2013-04-25$0.08/sh150,000$12,00016,682,019 total(indirect: see footnote)
  • Conversion

    Series E Convertible Preferred Stock

    2013-04-26$1000.00/sh200$200,0001,600 total(indirect: see footnote)
    Exercise: $0.02From: 2013-04-26Common Stock (8,230,453 underlying)
  • Disposition to Issuer

    Common Stock

    2013-04-26$0.08/sh243,926$19,56316,438,093 total(indirect: see footnote)
  • Disposition to Issuer

    Common Stock

    2013-04-29$0.08/sh130,000$10,40024,538,546 total(indirect: see footnote)
  • Other

    Warrants

    2001-04-2613,272,99926,272,001 total(indirect: see footnote)
    Exercise: $0.06From: 2009-10-30Exp: 2016-10-30Common Stock (13,272,999 underlying)
Footnotes (10)
  • [F1]Ram Potti is an equity owner and executive officer of each of Epic Pharma, LLC ("EP"), and Epic Investments, LLC ("EI") (which is controlled by EP), which owns securities convertible into or exercisable for in excess of 10% of the outstanding shares of common stock of the issuer.
  • [F10]N/A
  • [F2]Of the 16,682,019 shares of common stock, 14,910,666 shares of common stock are owned indirectly through EI and 416,339 shares are owned directly by the reporting person.
  • [F3]Of the 16,438,093 shares of common stock, 14,666,740 shares of common stock are owned indirectly through EI and 416,339 shares are owned directly by the reporting person
  • [F4]Of the 24,668,546 shares of common stock, 22,897,193 shares of common stock are owned indirectly through EI and 416,339 shares are owned directly by the reporting person
  • [F5]Of the 24,538,546 shares of common stock, 22,767,193 shares of common stock are owned indirectly through EI and 416,339 shares are owned directly by the reporting person
  • [F6]Of the 15,626,892 shares of common stock, 9,399,712 shares of common stock are owned indirectly through EI and 416,339 shares are owned directly by the reporting person
  • [F7]Conversion of Series E Preferred Stock of issuer at the rate of approximately 41,152.26 shares of common for each share of such preferred stock.
  • [F8]Disposition of shares to its members
  • [F9]Disposition of warrants to its members

Issuer

ELITE PHARMACEUTICALS INC /NV/

CIK 0001053369

Entity typeother

Related Parties

1
  • filerCIK 0001465824

Filing Metadata

Form type
4
Filed
Apr 29, 8:00 PM ET
Accepted
Apr 30, 3:07 PM ET
Size
18.2 KB